ACSL1 and neoplasm: In conclusion, our study identified a genetic variant in the 3’-UTR region of ACSL1 gene (rs8086) that may play a significant role in predicting outcomes of stage II/III patients with CC, so that patients with T/T genotype had a significantly higher risk of tumor recurrence than those carrying at least one C allele.